Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
However, our pharmacy can compound it into tablets and solutions that can go under the tongue, or into a lozenge-like formulation called a troche
It requires the guidance of a n experienced medical professional who can tailor the protocol to your unique biochemistry and health goals
X 2 Gov/24399880/ 3 4 5 6 Wiley.Com/doi/10.1111/j.1524-4725.1996
BPC-157 and TB-500 target tissue repair through genuinely different mechanisms they complement each other rather than duplicate the same pathway